Kalaris Therapeutics Inc

KLRS · NASDAQ
Analyze with AI
9/30/2025
6/30/2025
3/31/2025
12/31/2024
Operating Activities
Net Income-$11,894-$11,350-$10,196
Dep. & Amort.$0$0$0
Deferred Tax$0$0$0
Stock-Based Comp.$0$0$374
Change in WC-$9-$1,780$2,346
Other Non-Cash$570-$1,755$35
Operating Cash Flow-$11,333-$14,885-$7,441
Investing Activities
PP&E Inv.-$183$0$0
Net Acquisitions$0$0$0
Inv. Purchases-$34,523$0$0
Inv. Sales/Matur.$0$0$0
Other Inv. Act.$0$0$0
Investing Cash Flow-$34,706$0$0
Financing Activities
Debt Repay.$0$7,500$7,500
Stock Issued$0$0$0
Stock Repurch.$0$0$0
Dividends Paid$0$0$0
Other Fin. Act.$0-$5,154$99,767
Financing Cash Flow$0$2,346$107,267
Forex Effect$0$0$0
Net Chg. in Cash-$46,039-$12,539$99,826
Supplemental Information
Beg. Cash$88,426$100,965$1,639
End Cash$42,387$88,426$101,465
Free Cash Flow-$11,516-$14,885-$7,441
Kalaris Therapeutics Inc (KLRS) Financial Statements & Key Stats | AlphaPilot